Which Drugs Work Best for ADHD? Large Study Zeroes in on Two
The researchers compared seven ADHD drugs -- amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate and modafinil -- and a placebo over 12 weeks of treatment.
In recognition of ADHD Awareness Month, NIMH will host a livestream event on October 21, 2020, from 1:00 - 1:30 p.m. ET, to discuss signs, symptoms, treatments, current research, and tips for helping children and adolescents manage ADHD during the pandemic.
Came across this while browsing a provider's website. I did some googling and the results mostly talked about where to get this certification and some providers who have it. Has anyone ever heard of this? Is it legit or just another way to pad the CV? Looking at the website, it seems that Evergreen Certifications (formerly IATP apparently) also offers several other certifications including anxiety, anger, and compassion fatigue. My scam radar is going off, but I figured I'd ask.
We present data on predictors and mediators of such risk, highlighting a recent dual-process model involving trait impulsivity plus family- and peer-related contributors. We conclude with recommendations for assessment and preventive intervention. PMID: 33019955 [PubMed - as supplied by publisher]
Publication date: Available online 4 October 2020Source: Journal of Psychiatric ResearchAuthor(s): Qi Zhang, Xinzhen Chen, Shanyawen Li, Ting Yao, Jing Wu
Publication date: Available online 6 October 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): Martine Hoogman, Marije Stolte, Matthijs Baas, Evelyn Kroesbergen
In this study, however, this was never done. As a result, we don’t learn whether beginning with combined medication and behavioral treatment may be superior to starting with either in isolation. Third, parents did not choose which treatment their child started with, or how treatment was augmented if their child’s response was not sufficient. Instead, random assignment was used to determine what treatment(s) children received. While this randomization is an essential part of a controlled study, in community settings, parents decide what initial and subsequent treatment their child receives. Thus, finding that pa...
Contributors : Joel T Nigg ; Tim McCaffrey ; Georges St.Laurent ; Daniel Jones ; Dmitry Shtokalo ; Denis Antonets ; Yuri Vyatkin ; Eleanor BattisonSeries Type : Expression profiling by genome tiling arrayOrganism : Homo sapiensWe found RNA markers common to both the discordant twin study and case-controlled subjects further narrowed the putative targets, some of which had been previously associated with ADHD at the DNA level. The potential role of several differentially expressed genes, including ABCB5, RGS2, GAK, GIT1 and 3 members of the galactose metabolism pathway (GALE, GALT, GALK1) are substantiated by prior associat...
Publication date: Available online 5 October 2020Source: Progress in Neuro-Psychopharmacology and Biological PsychiatryAuthor(s): Christian Hyde, Ian Fuelscher, Emma Sciberras, Daryl Efron, Vicki A. Anderson, Tim Silk
This study assessed the impact of a recent (within past year) diagnosis of a mental disorder - including attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, depression and schizophrenia - on the risk for COVID-19 infection and related mortality and hospitalization rates. We analyzed a nation-wide database of electronic health records of 61 million adult patients from 360 hospitals and 317,000 providers, across 50 states in the US, up to July 29, 2020. Patients with a recent diagnosis of a mental disorder had a significantly increased risk for COVID-19 infection, an effect strongest for depression (adjusted o...